These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24415460)

  • 1. Generation and epitope mapping of a sub-group cross-reactive anti-respiratory syncytial virus G glycoprotein monoclonal antibody which is protective in vivo.
    Robinson MJ; Tan CS; Fenwick F; Chambers CJ; Routledge EG; Toms GL
    J Med Virol; 2014 Jul; 86(7):1267-77. PubMed ID: 24415460
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Protection of mice against Human respiratory syncytial virus by wild-type and aglycosyl mouse-human chimaeric IgG antibodies to subgroup-conserved epitopes on the G glycoprotein.
    Mekseepralard C; Toms GL; Routledge EG
    J Gen Virol; 2006 May; 87(Pt 5):1267-1273. PubMed ID: 16603529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the binding of monoclonal and polyclonal antibodies to the glycoproteins of antigenic variants of human respiratory syncytial virus by surface plasmon resonance.
    McGill A; Marsh R; Craft AW; Toms GL
    J Immunol Methods; 2005 Feb; 297(1-2):143-52. PubMed ID: 15777938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of multiple protective epitopes (protectopes) in the central conserved domain of a prototype human respiratory syncytial virus G protein.
    Plotnicky-Gilquin H; Goetsch L; Huss T; Champion T; Beck A; Haeuw JF; Nguyen TN; Bonnefoy JY; Corvaïa N; Power UF
    J Virol; 1999 Jul; 73(7):5637-45. PubMed ID: 10364313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influenza virus vaccine expressing fusion and attachment protein epitopes of respiratory syncytial virus induces protective antibodies in BALB/c mice.
    Bian C; Liu S; Liu N; Zhang G; Xing L; Song Y; Duan Y; Gu H; Zhou Y; Zhang P; Li Z; Zhang K; Wang Z; Zhang S; Wang X; Yang P
    Antiviral Res; 2014 Apr; 104():110-7. PubMed ID: 24509239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibody against G Glycoprotein Increases Respiratory Syncytial Virus Clearance In Vivo and Prevents Vaccine-Enhanced Diseases.
    Lee HJ; Lee JY; Park MH; Kim JY; Chang J
    PLoS One; 2017; 12(1):e0169139. PubMed ID: 28076422
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased susceptibility of human respiratory syncytial virus to neutralization by anti-fusion protein antibodies on adaptation to replication in cell culture.
    Marsh R; Connor A; Gias E; Toms GL
    J Med Virol; 2007 Jun; 79(6):829-37. PubMed ID: 17457900
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of human respiratory syncytial virus A2 and 8/60 fusion glycoprotein gene sequences and mapping of sub-group specific antibody epitopes.
    Connor AL; Bevitt DJ; Toms GL
    J Med Virol; 2001 Feb; 63(2):168-77. PubMed ID: 11170054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients.
    Collarini EJ; Lee FE; Foord O; Park M; Sperinde G; Wu H; Harriman WD; Carroll SF; Ellsworth SL; Anderson LJ; Tripp RA; Walsh EE; Keyt BA; Kauvar LM
    J Immunol; 2009 Nov; 183(10):6338-45. PubMed ID: 19841167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antigenic structure of the human respiratory syncytial virus G glycoprotein and relevance of hypermutation events for the generation of antigenic variants.
    Martínez I; Dopazo J; Melero JA
    J Gen Virol; 1997 Oct; 78 ( Pt 10)():2419-29. PubMed ID: 9349460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Production and characterization of monoclonal antibodies against different epitopes of Ebola virus antigens.
    Shahhosseini S; Das D; Qiu X; Feldmann H; Jones SM; Suresh MR
    J Virol Methods; 2007 Jul; 143(1):29-37. PubMed ID: 17368819
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody.
    Corti D; Bianchi S; Vanzetta F; Minola A; Perez L; Agatic G; Guarino B; Silacci C; Marcandalli J; Marsland BJ; Piralla A; Percivalle E; Sallusto F; Baldanti F; Lanzavecchia A
    Nature; 2013 Sep; 501(7467):439-43. PubMed ID: 23955151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of antibodies directed against human respiratory syncytial virus antigens present in two commercial preparations of human immunoglobulins with different neutralizing activities.
    Sastre P; Melero JA; García-Barreno B; Palomo C
    Vaccine; 2004 Dec; 23(4):435-43. PubMed ID: 15530691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polyclonal and monoclonal antibodies specific for the six-helix bundle of the human respiratory syncytial virus fusion glycoprotein as probes of the protein post-fusion conformation.
    Palomo C; Mas V; Vázquez M; Cano O; Luque D; Terrón MC; Calder LJ; Melero JA
    Virology; 2014 Jul; 460-461():119-27. PubMed ID: 25010277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Plasmid construction, expression, immunogenicity and protective efficacy of recombinant protein candidate vaccine of respiratory syncytial virus].
    Zeng RH; Gong W; Fang XP; Zhang ZY; Mei XG
    Sheng Wu Gong Cheng Xue Bao; 2005 Jul; 21(4):534-9. PubMed ID: 16176088
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Monoclonal Antibodies Against the Human Respiratory Syncytial Virus Obtained by Immunization with Epitope Peptides and CpG-DNA-liposome Complex.
    Park BK; Choi SH; Kim YE; Park S; Lee Y; Lee KW; Kwon HJ
    Monoclon Antib Immunodiagn Immunother; 2015 Apr; 34(2):101-9. PubMed ID: 25897608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
    Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
    Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prophylaxis with respiratory syncytial virus F-specific humanized monoclonal antibody delays and moderately suppresses the native antibody response but does not impair immunity to late rechallenge.
    Fisher RG; Johnson JE; Dillon SB; Parker RA; Graham BS
    J Infect Dis; 1999 Sep; 180(3):708-13. PubMed ID: 10438358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal immunization with a replication-deficient adenoviral vector expressing the fusion glycoprotein of respiratory syncytial virus elicits protective immunity in BALB/c mice.
    Fu Y; He J; Zheng X; Wu Q; Zhang M; Wang X; Wang Y; Xie C; Tang Q; Wei W; Wang M; Song J; Qu J; Zhang Y; Wang X; Hong T
    Biochem Biophys Res Commun; 2009 Apr; 381(4):528-32. PubMed ID: 19233131
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy using monoclonal antibodies against respiratory syncytial virus (RSV) G glycoprotein protects from RSV disease in BALB/c mice.
    Caidi H; Harcourt JL; Tripp RA; Anderson LJ; Haynes LM
    PLoS One; 2012; 7(12):e51485. PubMed ID: 23300550
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.